ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Organon and Co

Organon and Co (OGN)

12.20
0.08
(0.66%)
Closed April 26 4:00PM
12.20
0.00
(0.00%)
After Hours: 6:58PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
12.20
Bid
-
Ask
-
Volume
2,732,313
11.91 Day's Range 12.255
10.45 52 Week Range 23.10
Market Cap
Previous Close
12.12
Open
12.04
Last Trade
25
@
12.2
Last Trade Time
Financial Volume
$ 33,149,222
VWAP
12.1323
Average Volume (3m)
3,651,977
Shares Outstanding
257,950,149
Dividend Yield
9.18%
PE Ratio
3.64
Earnings Per Share (EPS)
3.35
Revenue
6.4B
Net Profit
864M

About Organon and Co

Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Geographically, it derives a majority of revenue from Europe and Canada. Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Geographically, it derives a majority of revenue from Europe and Canada.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
Organon and Co is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker OGN. The last closing price for Organon was $12.12. Over the last year, Organon shares have traded in a share price range of $ 10.45 to $ 23.10.

Organon currently has 257,950,149 shares outstanding. The market capitalization of Organon is $3.13 billion. Organon has a price to earnings ratio (PE ratio) of 3.64.

Organon (OGN) Options Flow Summary

Overall Flow

Bearish

Net Premium

-49k

Calls / Puts

0.00%

Buys / Sells

100.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

OGN Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
11.1610.507246376811.0412.210.45535357711.42273495CS
4-2.29-15.804002760514.4914.93510.45435636212.1971939CS
12-3.7-23.270440251615.917.2310.45365197714.04788488CS
26-5.07-29.357266936917.2719.04510.45351210514.81313861CS
52-6.42-34.479054779818.6223.110.45264696516.64441766CS
156-19.8-61.8753239.0910.45256669719.5220399CS
260-22-64.327485380134.239.47510.45258152822.58787998CS

OGN - Frequently Asked Questions (FAQ)

What is the current Organon share price?
The current share price of Organon is $ 12.20
How many Organon shares are in issue?
Organon has 257,950,149 shares in issue
What is the market cap of Organon?
The market capitalisation of Organon is USD 3.13B
What is the 1 year trading range for Organon share price?
Organon has traded in the range of $ 10.45 to $ 23.10 during the past year
What is the PE ratio of Organon?
The price to earnings ratio of Organon is 3.64
What is the cash to sales ratio of Organon?
The cash to sales ratio of Organon is 0.49
What is the reporting currency for Organon?
Organon reports financial results in USD
What is the latest annual turnover for Organon?
The latest annual turnover of Organon is USD 6.4B
What is the latest annual profit for Organon?
The latest annual profit of Organon is USD 864M
What is the registered address of Organon?
The registered address for Organon is CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Organon website address?
The website address for Organon is www.organon.com
Which industry sector does Organon operate in?
Organon operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
RBOTVicarious Surgical Inc
$ 8.50
(27.82%)
52.15k
SSTSystem1 Inc
$ 0.42
(25.71%)
647.37k
BBAIBigBear ai Holdings Inc
$ 3.5311
(21.34%)
125.63M
SESSES AI Corporation
$ 1.0293
(18.46%)
81.33M
CCMConcord Medical Services Holdings Ltd
$ 5.317
(16.60%)
51.42k
AZULAzul SA
$ 0.84
(-25.66%)
60.12M
FINS.RTAngel Oak Financial Strategies Income Term Trust
$ 0.0299
(-23.33%)
618.1k
AVTRAvantor Inc
$ 12.925
(-16.61%)
43.6M
KNSLKinsale Capital Group Inc
$ 420.00
(-16.33%)
951k
BHVNBiohaven Ltd
$ 19.83
(-15.26%)
6.16M
BBAIBigBear ai Holdings Inc
$ 3.5311
(21.34%)
125.63M
FFord Motor Company
$ 10.03
(-0.30%)
88.68M
SESSES AI Corporation
$ 1.0293
(18.46%)
81.33M
AZULAzul SA
$ 0.84
(-25.66%)
60.12M
ABEVAmbev SA
$ 2.47
(0.41%)
50.32M

OGN Discussion

View Posts
Monksdream Monksdream 1 year ago
OGN not so hot from a chart standpoint
👍️0
LordDarley LordDarley 4 years ago
Looks good.
There is also a very nice analysis on seeking Alpha. Shows pros and cons, and is professional quality IMHO. Much more detail than the Barron's article.
👍️0
DewDiligence DewDiligence 4 years ago
Barron’s bullish on OGN:

https://www.barrons.com/articles/jobs-report-fed-interest-rates-inflation-51622846230 Organon (OGN), which Merck (MRK) jettisoned this past week, could be another winner. This is a classic spinoff situation. Organon is a group of noncore Merck businesses—off-patent drugs sold mainly overseas, biosimilars, and a women’s health business—that may fare better as an independent company.
“You easily can see how this business could have been lost inside of Merck and been undermanaged relative to the rest of the portfolio,” says James Hounsell, a senior research analyst at Smead Capital Management, a Merck shareholder. “That’s when the magic happens with spinoffs.”

The shares trade around $34, giving the company a market value of $8.6 billion, plus about $9 billion of net debt. Merck shareholders received one Organon share for every 10 of Merck. Organon trades for just six times 2020 profits of $5.90 a share. Similar earnings are expected this year.

Organon isn’t as cheap when valued against projected 2021 earnings before interest, taxes, depreciation, and amortization, or Ebitda, of $2.3 billion, based on its enterprise value of equity value plus net debt. Then, it trades around eight times, in line with mature drug companies.

At a May investor day, Merck projected $6.1 billion to $6.4 billion of 2021 revenue for Organon and annual sales increases in the low- to mid-single digits. The dividend hasn’t been set yet, but based on Organon’s financial guidance, it could be about 3%.

Major drivers for the company are expected to be an implantable women’s contraceptive called Nexplanon and biosimilars, which are generic versions of bioengineered drugs.

“This is a stable, predictable business with low- to mid-single digit growth organically,” Organon CEO Kevin Ali tells Barron’s. He is bullish on the growth outlook for the women’s health business, now about 25% of revenue, plus the opportunity for potential acquisitions.

Given its low price/earnings ratio, Organon has good appreciation potential if it can deliver on its financial goals.
👍️0
DewDiligence DewDiligence 4 years ago
OGN spin-off from MRK begins trading today:

https://www.businesswire.com/news/home/20210602006079/en
👍️0

Your Recent History

Delayed Upgrade Clock